Excessive Aortic Inflammation in Chronic Obstructive Pulmonary Disease: An 18F-FDG PET Pilot Study

Chronic obstructive pulmonary disease (COPD) patients exhibit increased cardiovascular risk, even after controlling for smoking. Inflammation may underlie this observation. Methods: We measured vascular inflammation in both COPD patients and controls using 18F-FDG PET/CT. Aortic inflammation was expressed as the target-to-background ratio (TBR) of the standardized uptake value in 7 COPD patients, 5 metabolic syndrome patients, and 7 ex-smokers. Results: Abdominal aortic mean TBR (±SD) was greater in COPD patients than in ex-smoker controls (1.60 ± 0.13 vs. 1.34 ± 0.15, P = 0.0001). Aortic arch and abdominal aorta mean TBRs were higher in metabolic syndrome patients than in COPD patients (aortic arch, 1.80 ± 0.18 vs. 1.53 ± 0.18, P = 0.001, and abdominal aorta, 1.71 ± 0.14 vs. 1.60 ± 0.13, P = 0.001). Conclusion: COPD patients exhibited aortic inflammation that fell between the aortic inflammation exhibited by ex-smokers and that by metabolic syndrome patients. This may in part explain the increased risk of cardiovascular disease in COPD patients.

[1]  Marc Faraggi,et al.  Arterial wall uptake of fluorodeoxyglucose on PET imaging in stable cancer disease patients indicates higher risk for cardiovascular events , 2008, Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology.

[2]  D. Sin,et al.  The relationship between reduced lung function and cardiovascular mortality: a population-based study and a systematic review of the literature. , 2005, Chest.

[3]  H. Sillesen,et al.  Molecular pathology in vulnerable carotid plaques: correlation with [18]-fluorodeoxyglucose positron emission tomography (FDG-PET). , 2009, European journal of vascular and endovascular surgery : the official journal of the European Society for Vascular Surgery.

[4]  Eun Jeong Lee,et al.  Reversal of Vascular 18F-FDG Uptake with Plasma High-Density Lipoprotein Elevation by Atherogenic Risk Reduction , 2008, Journal of Nuclear Medicine.

[5]  Y. Sheikine,et al.  FDG-PET imaging of atherosclerosis: Do we know what we see? , 2010, Atherosclerosis.

[6]  H. Sillesen,et al.  Gene expression and 18FDG uptake in atherosclerotic carotid plaques , 2010, Nuclear medicine communications.

[7]  T. Imaizumi,et al.  Vascular inflammation evaluated by [18F]-fluorodeoxyglucose positron emission tomography is associated with the metabolic syndrome. , 2007, Journal of the American College of Cardiology.

[8]  A Senthilselvan,et al.  Association between chronic obstructive pulmonary disease and systemic inflammation: a systematic review and a meta-analysis , 2004, Thorax.

[9]  Peter H Edwards,et al.  Arterial stiffness and osteoporosis in chronic obstructive pulmonary disease. , 2007, American journal of respiratory and critical care medicine.

[10]  V. Fuster,et al.  Imaging atherosclerotic plaque inflammation by fluorodeoxyglucose with positron emission tomography: ready for prime time? , 2010, Journal of the American College of Cardiology.

[11]  A. Ionescu,et al.  Associated loss of fat-free mass and bone mineral density in chronic obstructive pulmonary disease. , 2004, American journal of respiratory and critical care medicine.

[12]  Robert A Wise,et al.  Ascertainment of cause-specific mortality in COPD: operations of the TORCH Clinical Endpoint Committee , 2007, Thorax.

[13]  I. Kubota,et al.  In vivo evidence of endothelial injury in chronic obstructive pulmonary disease by lung scintigraphic assessment of (123)I-metaiodobenzylguanidine. , 2003, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[14]  G. Musch,et al.  Spatial Heterogeneity of Lung Perfusion Assessed with 13N PET as a Vascular Biomarker in Chronic Obstructive Pulmonary Disease , 2010, Journal of Nuclear Medicine.

[15]  V. Fuster,et al.  Relationships Among Regional Arterial Inflammation, Calcification, Risk Factors, and Biomarkers: A Prospective Fluorodeoxyglucose Positron-Emission Tomography/Computed Tomography Imaging Study , 2009, Circulation. Cardiovascular imaging.

[16]  D. Owens,et al.  Insulin Resistance and inflammation—A Further Systemic Complication of COPD , 2007, COPD.

[17]  M. Reiser,et al.  18F-fluoroethylcholine uptake in arterial vessel walls and cardio vascular risk factors , 2010, Nuklearmedizin.

[18]  Ahmed Tawakol,et al.  In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. , 2006, Journal of the American College of Cardiology.

[19]  Masatoshi Ishibashi,et al.  Simvastatin attenuates plaque inflammation: evaluation by fluorodeoxyglucose positron emission tomography. , 2006, Journal of the American College of Cardiology.

[20]  J. Pickard,et al.  Imaging Atherosclerotic Plaque Inflammation With [18F]-Fluorodeoxyglucose Positron Emission Tomography , 2002, Circulation.